3.7(top 10%)
impact factor
1.9K(top 10%)
papers
58.5K(top 5%)
citations
100(top 5%)
h-index
4.2(top 10%)
impact factor
2.2K
all documents
61.8K
doc citations
141(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and inductionExpert Opinion on Drug Metabolism and Toxicology20061,122
2Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamilyExpert Opinion on Drug Metabolism and Toxicology2008646
3The Simcyp®Population-based ADME SimulatorExpert Opinion on Drug Metabolism and Toxicology2009438
4Caco-2 cell permeability assays to measure drug absorptionExpert Opinion on Drug Metabolism and Toxicology2005408
5The Caco-2 cell monolayer: usefulness and limitationsExpert Opinion on Drug Metabolism and Toxicology2008367
6Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamilyExpert Opinion on Drug Metabolism and Toxicology2008312
7Antisense oligonucleotide pharmacokinetics and metabolismExpert Opinion on Drug Metabolism and Toxicology2009259
8Zebrafish assays for drug toxicity screeningExpert Opinion on Drug Metabolism and Toxicology2006245
9Species differences in drug transporters and implications for translating preclinical findings to humansExpert Opinion on Drug Metabolism and Toxicology2013239
10Cytochrome P450 variations in different ethnic populationsExpert Opinion on Drug Metabolism and Toxicology2012227
11Development of inhibitors of ATP-binding cassette drug transporters – present status and challengesExpert Opinion on Drug Metabolism and Toxicology2008225
12The effect of chronic renal failure on drug metabolism and transportExpert Opinion on Drug Metabolism and Toxicology2008200
13Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessmentExpert Opinion on Drug Metabolism and Toxicology2008200
14Minimising the potential for metabolic activation in drug discoveryExpert Opinion on Drug Metabolism and Toxicology2005198
15Toxicity of MRI and CT contrast agentsExpert Opinion on Drug Metabolism and Toxicology2009195
16Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugsExpert Opinion on Drug Metabolism and Toxicology2009194
17Glutathione S-transferases: an overview in cancer researchExpert Opinion on Drug Metabolism and Toxicology2010190
18Role of CAR and PXR in xenobiotic sensing and metabolismExpert Opinion on Drug Metabolism and Toxicology2012188
19Structure and function of the MRP2 (ABCC2) protein and its role in drug dispositionExpert Opinion on Drug Metabolism and Toxicology2006187
20The HepaRG cell line: a uniquein vitrotool for understanding drug metabolism and toxicology in humanExpert Opinion on Drug Metabolism and Toxicology2012187
21The influence of gut microbiota on drug metabolism and toxicityExpert Opinion on Drug Metabolism and Toxicology2016187
22ABCG2: structure, function and role in drug responseExpert Opinion on Drug Metabolism and Toxicology2008182
23Sertindole: pharmacological and clinical profile and role in the treatment of schizophreniaExpert Opinion on Drug Metabolism and Toxicology2008180
24Hepatocyte cell lines: their use, scope and limitations in drug metabolism studiesExpert Opinion on Drug Metabolism and Toxicology2006173
25The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disordersExpert Opinion on Drug Metabolism and Toxicology2007173
26Intestinal efflux transporters and drug absorptionExpert Opinion on Drug Metabolism and Toxicology2008173
27Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionExpert Opinion on Drug Metabolism and Toxicology2011173
28Toxicological considerations when creating nanoparticle-based drugs and drug delivery systemsExpert Opinion on Drug Metabolism and Toxicology2012172
29The rise of PAMPAExpert Opinion on Drug Metabolism and Toxicology2005171
30In vitromodels of the human epithelial airway barrier to study the toxic potential of particulate matterExpert Opinion on Drug Metabolism and Toxicology2008171
31Whole-body physiologically based pharmacokinetic modelsExpert Opinion on Drug Metabolism and Toxicology2007165
32The effect of grapefruit juice on drug dispositionExpert Opinion on Drug Metabolism and Toxicology2011164
33Luminogenic cytochrome P450 assaysExpert Opinion on Drug Metabolism and Toxicology2006156
34The role of CYP26 enzymes in retinoic acid clearanceExpert Opinion on Drug Metabolism and Toxicology2009154
35Pharmacokinetic properties and drug interactions of apigenin, a natural flavoneExpert Opinion on Drug Metabolism and Toxicology2017153
36The influence of circadian rhythms on the kinetics of drugs in humansExpert Opinion on Drug Metabolism and Toxicology2008152
37Competency of different cell models to predict human hepatotoxic drugsExpert Opinion on Drug Metabolism and Toxicology2014152
38Drug-induced mitochondrial toxicityExpert Opinion on Drug Metabolism and Toxicology2005149
39Regulation of drug metabolism and disposition during inflammation and infectionExpert Opinion on Drug Metabolism and Toxicology2005148
40The role of aldehyde oxidase in drug metabolismExpert Opinion on Drug Metabolism and Toxicology2012147
41The role of drug metabolizing enzymes in clearanceExpert Opinion on Drug Metabolism and Toxicology2014146
42Ambroxol in the 21st century: pharmacological and clinical updateExpert Opinion on Drug Metabolism and Toxicology2008144
43In silicoADME-Tox modeling: progress and prospectsExpert Opinion on Drug Metabolism and Toxicology2017144
44Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicineExpert Opinion on Drug Metabolism and Toxicology2018144
45Dexmedetomidine: sedation, analgesia and beyondExpert Opinion on Drug Metabolism and Toxicology2008143
46Liver tissue engineering in the evaluation of drug safetyExpert Opinion on Drug Metabolism and Toxicology2009143
47Is curcumin bioavailability a problem in humans: lessons from clinical trialsExpert Opinion on Drug Metabolism and Toxicology2019140
48The road map to oral bioavailability: an industrial perspectiveExpert Opinion on Drug Metabolism and Toxicology2006139
49ABCG2: the key to chemoresistance in cancer stem cells?Expert Opinion on Drug Metabolism and Toxicology2009138
50Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediationExpert Opinion on Drug Metabolism and Toxicology2010138